Coronavirus assay development

Ended Awarded Last action

Contract number
W911QY20F0125
Awardee
Awarding agency
Obligated
$2,384,846

Award facts

Opportunity
Contract value 100% obligated
$2,384,846.07 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Millcreek, UT 84107, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order P00010 $0
Change Order P00009 $0
Change Order P00008 $304,450
Change Order P00007 · Emerging non-biological warfare threat r $0
Supplemental Agreement for work within scope P00006 · Emerging non-biological warfare threat - FDA required testing for covid-19 assay development. $0
Supplemental Agreement for work within scope P00005 · Sample pooling work $0
Definitize Change Order P00004 · Emerging non-biological warfare threat r $0
Change Order P00003 · Emerging non-biological warfare threat r change order to revise statement of work. $0
Definitize Change Order P00002 · Coronavirus assay development definitizing change order modification. $341,400
Change Order P00001 · Coronavirus assay development change order to request live virus testing. $0
Original award $1,738,996
Show all 11

About this award

This federal contract award to Biofire Defense LLC, a for-profit limited liability company based in Salt Lake City, Utah, is for the development of COVID-19 assays. The $2,384,846.07 contract was awarded on February 14, 2020 by the U.S. Army's Joint Project Executive Office for Chemical and Biological Defense, a defense agency. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type and an ultimate completion date of July 1, 2022. This award is associated with a larger Indefinite Delivery Vehicle held by Biofire Defense, indicating the company is a preferred vendor for advanced diagnostic solutions across multiple federal agencies. The contract does not utilize a set-aside designation. Biofire Defense has been awarded additional federal contracts and grants, including a $6.2 million cooperative agreement focused on expanding COVID-19 test production capacity. The company's subcontractor on this award is Mriglobal, a not-for-profit research organization in Kansas City, Missouri, which is validating the Biofire COVID-19 test.

Quick answers

Who was awarded contract W911QY20F0125?

W911QY20F0125 was awarded to Biofire Defense LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on February 14, 2020.

How much is contract W911QY20F0125 worth?

The government has obligated $2,384,846 on W911QY20F0125.

Which agency awarded contract W911QY20F0125?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY20F0125, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Is contract W911QY20F0125 an order under another contract?

Yes. W911QY20F0125 is a delivery order under W911QY13D0080, an indefinite delivery contract.

Was contract W911QY20F0125 competed?

The extent of competition for W911QY20F0125 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award